Bui M H, Zisman A, Pantuck A J, Han K R, Wieder J, Belldegrun A S
University of California School of Medicine, Department of Urology, 10833 Le Conte Avenue, Room 66-118 CHS, Los Angeles, CA 90095-1738, USA.
Expert Rev Anticancer Ther. 2001 Dec;1(4):565-75. doi: 10.1586/14737140.1.4.565.
Renal cell carcinoma is the most common cancer in the kidney, affecting nearly 30,000 Americans every year and is associated with over 12,000 deaths annually. If detected early, renal cell carcinomas can be cured surgically. However, once metastatic disease develops the prognosis for long-term survival is poor. Unfortunately, one-third of patients have metastatic disease at the time of diagnosis and approximately 50% of the patients undergoing surgical resection for less advanced disease eventually relapse. This review examines the clinical and molecular prognostic tools currently available or under investigation for kidney cancer.
肾细胞癌是肾脏最常见的癌症,每年影响近30000名美国人,每年导致超过12000人死亡。如果早期发现,肾细胞癌可以通过手术治愈。然而,一旦发生转移性疾病,长期生存的预后就很差。不幸的是,三分之一的患者在诊断时就有转移性疾病,对于病情较轻的疾病接受手术切除的患者中,约50%最终会复发。本综述探讨了目前可用于或正在研究的肾癌临床和分子预后工具。